Yahoo!   My Yahoo!   Mail  
Search   
Sign In
New User? Sign Up
Home > Investing > ACAD > Summary

ACADIA Pharmaceuticals, Inc.
(ACAD)

1.30USD   Up0.03 (2.36%)   
At 2:30AM IST
 ACADIA Pharmaceuticals, Inc. (NGM:ACAD) Delayed quote data 
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Last Trade: 1.30USD
Trade Time:2:30AM IST
Change:Up0.03 (2.36%)
Prev Close:1.27
Open:1.28
Bid:1.10 x 5000
Ask:2.20 x 100
1y Target Est:2.83
Day's Range:1.25 - 1.32
52wk Range:0.75 - 6.60
Volume:383,078
Avg Vol (3m):591,383
Market Cap:49.75M
P/E (ttm):N/A
EPS (ttm):-1.35
Div & Yield:N/A (N/A%)
Add ACAD to Portfolio   Download Data

HEADLINES

 
•ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 8, 2010 - Business Wire  - Mon, Feb 1
•ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement - EDGAR Online  - Fri, Jan 29
•ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Finan - EDGAR Online  - Fri, Dec 18
•ACADIA PHARMACEUTICALS INC Financials - EDGAR Online Financials  - Sat, Nov 14
•RHI Entertainment, Opnext: Midday Volume Plays - TheStreet.com  - Tue, Nov 10
•ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an - EDGAR Online  - Tue, Nov 10
•ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors - EDGAR Online  - Fri, Oct 16
•ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement - EDGAR Online  - Tue, Oct 6
•Mannkind Falls on Talk of Partner, FDA Delay: BioBuzz - TheStreet.com  - Tue, Oct 6
•No Lupus Confab Invite for Immunomedics: BioBuzz - TheStreet.com  - Tue, Oct 6
» More Headlines for ACAD...

ANALYST

 
EPS Est (next year) (Dec-09) :-1.17
EPS Est (in 2 years) (Dec-10) :-0.60
Avg Rec (current)*:3.3
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
» Analyst Opinion» Estimates

BUSINESS SUMMARY

 
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.

» Full Company Profile